Transcode TherapeuticsRNAZ
13F holders, Q4 2025 (December 31)6holders −2
1new positions
3sold out
$6.82avg. 13F price*
At the end of Q4 2025, 6 institutions reported holding Transcode Therapeutics Inc. (RNAZ) in their 13F filings, down 2 from Q3 2025. 1 opened new positions and 3 sold out. The largest holders were UBS Group AG ($20K), Tower Research Capital LLC (TRC) ($6K) and SBI Securities Co., Ltd. ($68).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L501
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $20K |
| Exits | 3 | $153K |
All 13F filers, Q3 2025 → Q4 2025: 3,709 shares bought and 14,263 shares sold, net −10,554 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | New | 2,964 | $20K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +524.6% | 887 | $6K |
| SBI Securities Co., Ltd. | 0.00% | No change | 10 | $68 |
| Bank of America Corp. | 0.00% | No change | 8 | $55 |
| Osaic Holdings, Inc. | 0.00% | No change | 3 | $20 |
| Royal Bank of Canada | 0.00% | No change | 8 | $0 |
"% of holder's portfolio" is RNAZ's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.